Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

Reginster, Jean Yves; Deroisy, Rita; Rovati, Lucio C.; Lee, Richard L; Lejeune, E; Bruyère, Olivier; Giacovelli, Giampaolo; Henrotin, Yves; Dacre, Jane; Gossett, Christiane

doi:10.1016/s0140-6736(00)03610-2

Cited by 1,089 publications

(872 citation statements)

References 18 publications

Supporting

Mentioning

753

Contrasting

Unclassified

Order By: Relevance

“…The use of indomethacin was not permitted because of its potential to promote degeneration of OA cartilage (13,(51)(52)(53). Likewise, the use of glucosamine sulfate was not permitted because of its potential to affect OA progression (54).…”

Section: Methodsmentioning

confidence: 99%

Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes

Raynauld¹,

Martel‐Pelletier²,

Berthiaume³

et al. 2004

Arthritis & Rheumatism

239

View full text Add to dashboard Cite

Objective. To evaluate the change in osteoarthritic (OA) knee cartilage volume over a two-year period with the use of magnetic resonance imaging (MRI) and to correlate the MRI changes with radiologic changes.Methods. Thirty-two patients with symptomatic knee OA underwent MRI of the knee at baseline and at 6, 12, 18, and 24 months. Loss of cartilage volumes were computed and contrasted with changes in clinical variables for OA and with standardized semiflexed knee radiographs at baseline at 1 and 2 years.Results. Progression of cartilage loss at all followup points was statistically significant (P < 0.0001), with a mean ؎ SD of 3.8 ؎ 5.1% for global cartilage loss and 4.3 ؎ 6.5% for medial compartment cartilage loss at 6 months, 3.6 ؎ 5.1% and 4.2 ؎ 7.5% at 12 months, and 6.1 ؎ 7.2% and 7.6 ؎ 8.6% at 24 months. Discriminant function analysis identified 2 groups of patients, those who progressed slowly (<2% of global cartilage loss; n ‫؍‬ 21) and those who progressed rapidly (>15% of global cartilage loss; n ‫؍‬ 11) over the 2 years of study. At baseline, there was a greater proportion of women (P ‫؍‬ 0.001), a lower range of motion (P ‫؍‬ 0.01), a greater circumference and higher level of pain (P ‫؍‬ 0.05) and stiffness in the study knee, and a higher body mass index in the fast progressor group compared with the slow progressor group. No statistical correlation between loss of cartilage volume and radiographic changes was seen.Conclusion. Quantitative MRI can measure the progression of knee OA precisely and can help to identify patients with rapidly progressing disease. These findings indicate that MRI could be helpful in assessing the effects of treatment with structure-modifying agents in OA.In people over the age of 60 years, osteoarthritis (OA) is a common cause of disability. Assessment of cartilage damage is important for monitoring disease progression and evaluating therapeutic response in OA. For many years, clinical studies of drug interventions in symptomatic knee OA have focused specifically on clinical parameters, such as pain and joint function, without assessing the effect of treatment on structural changes caused by the disease or the role of treatment in preventing cartilage degradation. Serial radiographs of affected joints appear to be a logical means of documenting the progression of OA over time (1), provided that a validated, reliable, and easily reproducible technique is used (2-5).

show abstract

Section: Methodsmentioning

confidence: 99%

Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes

Raynauld¹,

Martel‐Pelletier²,

Berthiaume³

et al. 2004

Arthritis & Rheumatism

239

View full text Add to dashboard Cite

show abstract

“…Coll2-1 and Coll2-1NO 2 have been found to be elevated in sera of patients with knee OA as well as in patients with rheumatoid arthritis (Henrotin et al, 2004;Deberg et al, 2005). These markers were also measured in urines of a cohort of 75 patients with knee OA corresponding to the placebo arm of a large 3-year, randomized, double-blind study comparing the efficacy of glucosamine sulphate with placebo (Reginster et al, 2001). At baseline, significant correlations were found between the urinary levels of Coll2-1 and Coll2-1NO 2 and the Global Western Ontario Mc master Universities (WOMAC) algo-functional score.…”

Section: Introductionmentioning

confidence: 99%

A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions

Gangl

Serteyn

Lejeune³

et al. 2007

Research in Veterinary Science

View full text Add to dashboard Cite

Markers of cartilage breakdown enable studying the degradation of cartilage matrix in equine joint pathologies. This study was designed to determine the levels of Coll2-1, a peptide of the triple helix of type II collagen, and Coll2-1NO 2 , its nitrated form in the plasma of healthy horses (controls; n = 37) and horses suffering from osteochondrosis (n = 34). Clinical and arthroscopic scores were attributed reflecting the severity of lesions and were related to the plasma levels of Coll2-1 and Coll2-1NO 2 . The median of Coll2-1 was significantly higher in the control group, whereas the mean of Coll2-1NO 2 showed significant elevation in the pathological group. However, the measurement means of scoring classes did not vary significantly. The markers were able to differentiate the group of horses suffering from osteochondrosis from the group of healthy horses. The elevation of Coll2-1NO 2 in the pathological group indicates an inflammation, mediated through reactive oxygen species and/or increased myeloperoxidase activity.

show abstract

“…To the Editor: Brandt and Mazzuca are to be commended for producing a thorough and informative systematic review on clinical trials of disease-modifying osteoarthritis (OA) drugs (1). However, we noted some imprecisions in the data reported for the glucosamine sulfate trials that were independently performed by our groups of investigators (2,3).…”

Section: To the Editormentioning

confidence: 95%

Clinical significance of the long‐term symptom‐modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca

Bruyère

Reginster

Giacovelli³

et al. 2006

Arthritis & Rheumatism

Self Cite

View full text Add to dashboard Cite

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial

Cited by 1,089 publications

References 18 publications

Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes

Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes

A type II-collagen derived peptide and its nitrated form as new markers of inflammation and cartilage degradation in equine osteochondral lesions

Clinical significance of the long‐term symptom‐modifying effects of glucosamine sulfate: Comment on the article by Brandt and Mazzuca

Contact Info

Product

Resources

About